Quarterly report pursuant to Section 13 or 15(d)

Acquisition (Details Narrative)

v3.19.3
Acquisition (Details Narrative) - USD ($)
9 Months Ended
Jul. 30, 2019
Jul. 15, 2019
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2019
Dec. 31, 2018
Proceeds from preferred stock financing     $ 13,087,000    
Goodwill   $ 8,300,000 8,273,000    
Finite lived intangible assets   $ 7,300,000 $ 7,600,000      
Finite lived intangible assets weighted-average amortization period   8 years 4 months 24 days        
Business transaction   $ 2,500,000        
Trademarks [Member]            
Finite lived intangible assets weighted-average amortization period   10 years        
Customer Relationships [Member]            
Finite lived intangible assets weighted-average amortization period   8 years        
CGI Bio Pharma [Member]            
Business combination consideration amount $ 775,000          
CGI Bio Pharma [Member] | Forecast [Member]            
Accounts receivable         $ 830,000  
Asset Purchase Agreement [Member] | Inital Tranche [Member]            
Proceeds from preferred stock financing   $ 13,800,000        
Asset Purchase Agreement [Member] | CGI Bio Pharma [Member]            
Assets and assumed certain liabilities   23,500,000        
Proceeds from preferred stock financing   7,692,300        
Asset Purchase Agreement [Member] | CGI Bio Pharma [Member] | Base Purchase Price [Member]            
Assets and assumed certain liabilities   $ 19,800,000